Pathologic Findings in Squamous Cell Bladder Carcinoma Overview of Squamous Cell Carcinoma
- Author: Muhammad T Idrees, MD; Chief Editor: Liang Cheng, MD more...
Overview of Squamous Cell Carcinoma
Squamous cell carcinoma (SCC) is the second most common cell type associated with bladder cancer in developed countries. In the United States, around 5% of bladder cancers are SCCs.[1, 2] Worldwide, however, SCC is the most common form of bladder cancer, accounting for 75% of cases in developing nations.
For more information, see Bladder Cancer, as well as Pathologic Findings in Small Cell Bladder Carcinoma and Cystoscopy.
Gross Findings in Squamous Cell Carcinoma
Cystoscopically, squamous cell carcinoma (SCC) appears nodular and has a plaquelike, irregular surface with involvement of multiple bladder sites. The lateral wall and trigone are more commonly involved.[3, 4] Grossly, the tumor seems nodular with deep invasion into the muscularis and often involves the extravesical organs. Most of the tumors are large, exophytic, and necrotic and bulge into the bladder cavity.[2, 5] Flat tumors with irregular borders are less common.[6] Surface necrosis and keratin debris are usually present, which give it a flaky, whitish appearance.
Microscopic Findings in Squamous Cell Carcinoma
Microscopically, the squamous cell tumors arise in epithelium and infiltrate in sheets, nests, and islands (see the images below); they resemble epidermal tumors, with some combination of individual cell keratinization, keratin pearls, and intercellular bridges. Transurethral resection of bladder tumor (TURBT) biopsies may contain only keratinous debris. Keratinization of cells at the stromal interface is a sign of invasion.
Cells are polygonal with well-defined cell borders and have amphophilic to eosinophilic cytoplasm. The nuclei are pleomorphic, occasionally bizarre, with irregular chromatin and prominent nucleoli. Mitotic figures are easily identifiable. Abundant degenerated cells are also seen in biopsy material. Squamous metaplasia has been seen in 17-60% of nonendemic cases.
Squamous cell carcinoma; note the infiltration into the muscularis propria by small nests and individual tumor cells. 
Squamous carcinoma in situ adjacent to the tumor. Verrucous squamous cell carcinoma
Verrucous SCC is a rare variant of squamous cell carcinoma of the bladder and accounts for less than 5% of the squamous cell carcinomas.[7, 8] Most cases are associated with Schistosoma haematobium infection. Few cases have been reported from nonendemic areas. The tumor has an indolent growth pattern and spreads by direct extension. It does not metastasize, although it may develop foci of invasive squamous cell carcinoma.[9]
Grossly the tumor is a warty, exophytic mass that projects into the bladder lumen.
Microscopically, it appears as a prominent papillary mass with acanthosis. The tumor grows in bulbous fronds of well-differentiated, acanthotic epithelium. There is minimal atypia and pushing margin without increased mitoses. It may focally resemble condyloma and has been reported to be associated with human papillomavirus (HPV); however, no firm link to HPV infection has been established.[10] Generally, the verrucous carcinoma is considered low risk for progression; however, this is difficult to establish in the bladder because of relatively fewer number of cases.
Basaloid squamous cell carcinoma
Only a single case of basaloid squamous cell carcinoma of the bladder has recently been reported, in a 60-year-old woman with incontinence, intractable urinary tract infections, and flat, cystoscopic lesions.[11] Microscopically, the tumor was composed of nests of basaloid cells with numerous mitoses, areas of squamous differentiation, and squamous cell carcinoma in situ. Bostwick and Cheng have proposed that the correct terminology should be urothelial carcinoma with basaloid features, rather than basaloid squamous cell carcinoma.[12]
Immunohistochemistry
The diagnosis of squamous cell carcinoma of the bladder is primarily based on the morphology. The immunohistochemical stains do not have a substantial role in diagnosing this tumor. CK20 has been seen in the majority of cases of urothelial carcinoma; however, in one study, none of the schistosomal-associated squamous cell carcinomas stained. COX-2 and uroplakin II expression has not been observed in any of the squamous cell carcinomas of the bladder, but they have been expressed in the majority of urothelial carcinomas.[13, 14]
Molecular Alterations and Genetics
The molecular data for the squamous cell carcinoma of the bladder has emerged mostly from the analysis of schistosomal-associated cases. Overrepresentation of 5p, 6p, 7p, 8q, 11q, 17q, and 20q of chromosomal material has been detected by cytogenetic and classic molecular analysis. In addition, deletions at 3p, 4q, 5q, 8p, 13q, 17p, and 18q have also been reported.[15, 16, 17, 18, 19, 20, 21]
As with urothelial carcinoma, a wide range of p53 positivity has been observed in schistosomal-associated squamous cell carcinoma in different studies.[22, 23, 24, 25] In one study, TP53 mutations in schistosomal-associated squamous cell carcinoma included more base transitions at CpG dinucleotides than seen in urothelial carcinomas.[25]
Other molecular alterations known to occur in urothelial carcinomas, such as HRAS mutations,[26, 27] epidermal growth factor receptor (EGFR) overexpression, and HER2 expression were also found at comparable frequencies in schistosomal-associated squamous cell carcinomas.[28] Methylation of DNA as shown by detection of O6-methyldeoxyguanosine has been found in a high percentage of patients with schistosomiasis-associated cancers in Egypt.[29, 30]
A few sporadic cases of squamous cell carcinoma examined by classic cytogenetics and comparative genomic hybridization (GCH) have shown gains at 1q, 8qa, and 20q, as well as losses of 3p, 9p, and 13q.[16, 31, 32, 33]
Squamous Cell Carcinoma Grading
The squamous cell tumor is generally graded as well differentiated, moderately differentiated, or poorly differentiated, depending on the extent of keratinization and nuclear pleomorphism.[6, 34, 35, 36] However, the grading system is not universally reproducible, as some authors believe that there is no direct correlation between the aggressiveness and the tumor grade.[6] Others believe that histologic grade influences the tumor stage and clinical outcome.[34, 35] Nuclear tetraploidy and aneuploidy correlate with the grade and stage of squamous cell carcinoma and adversely affect survival.[36, 37]
Rous SN. Squamous cell carcinoma of the bladder. J Urol. Nov 1978;120(5):561-2. [Medline].
Sarma KP. Squamous cell carcinoma of the bladder. Int Surg. May 1970;53(5):313-9. [Medline].
Sakkas JL. Clinical pattern and treatment of squamous cell carcinoma of the bladder. Int Surg. Jan 1966;45(1):71-6. [Medline].
Johnson DE, Schoenwald MB, Ayala AG, Miller LS. Squamous cell carcinoma of the bladder. J Urol. May 1976;115(5):542-4. [Medline].
Bessette PL, Abell MR, Herwig KR. A clinicopathologic study of squamous cell carcinoma of the bladder. J Urol. Jul 1974;112(1):66-7. [Medline].
Newman DM, Brown JR, Jay AC, Pontius EE. Squamous cell carcinoma of the bladder. J Urol. Oct 1968;100(4):470-3. [Medline].
Holck S, Jørgensen L. Verrucous carcinoma of urinary bladder. Urology. Oct 1983;22(4):435-7. [Medline].
Blackmore CC, Ratcliffe NR, Harris RD. Verrucous carcinoma of the bladder. Abdom Imaging. Sep-Oct 1995;20(5):480-2. [Medline].
Boileau M, Hui KK, Cowan DF. Invasive verrucous carcinoma of urinary bladder treated by irradiation. Urology. Jan 1986;27(1):56-9. [Medline].
Walther M, O'Brien DP 3rd, Birch HW. Condylomata acuminata and verrucous carcinoma of the bladder: case report and literature review. J Urol. Feb 1986;135(2):362-5. [Medline].
Vakar-López F, Abrams J. Basaloid squamous cell carcinoma occurring in the urinary bladder. Arch Pathol Lab Med. Mar 2000;124(3):455-9. [Medline].
Bostwick GD, Cheng L. Neoplasms of the urinary bladder. In: Bostwick GD, Cheng L, eds. Urologic Surgical Pathology: Expert Consult. 2nd ed. Philadelphia, Pa: Elsevier/Mosby; 2008:309.
Wu RL, Osman I, Wu XR, Lu ML, Zhang ZF, Liang FX, et al. Uroplakin II gene is expressed in transitional cell carcinoma but not in bilharzial bladder squamous cell carcinoma: alternative pathways of bladder epithelial differentiation and tumor formation. Cancer Res. Mar 15 1998;58(6):1291-7. [Medline]. [Full Text].
Gee JR, Montoya RG, Khaled HM, Sabichi AL, Grossman HB. Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder. Urol Oncol. Jul-Aug 2003;21(4):266-70. [Medline].
Aly MS, Khaled HM. Chromosomal aberrations in early-stage bilharzial bladder cancer. Cancer Genet Cytogenet. Jan 1 2002;132(1):41-5. [Medline].
El-Rifai W, Kamel D, Larramendy ML, Shoman S, Gad Y, Baithun S, et al. DNA copy number changes in Schistosoma-associated and non-Schistosoma-associated bladder cancer. Am J Pathol. Mar 2000;156(3):871-8. [Full Text].
Fadl-Elmula I, Kytola S, Leithy ME, Abdel-Hameed M, Mandahl N, Elagib A, et al. Chromosomal aberrations in benign and malignant bilharzia-associated bladder lesions analyzed by comparative genomic hybridization. BMC Cancer. Mar 22 2002;2:5. [Full Text].
Gonzalez-Zulueta M, Shibata A, Ohneseit PF, Spruck CH 3rd, Busch C, Shamaa M, et al. High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder. J Natl Cancer Inst. Sep 20 1995;87(18):1383-93. [Medline].
Muscheck M, Abol-Enein H, Chew K, Moore D 2nd, Bhargava V, Ghoneim MA, et al. Comparison of genetic changes in schistosome-related transitional and squamous bladder cancers using comparative genomic hybridization. Carcinogenesis. Sep 2000;21(9):1721-6. [Medline].
Pycha A, Mian C, Posch B, Haitel A, Mokhtar AA, El-Baz M, et al. Numerical chromosomal aberrations in muscle invasive squamous cell and transitional cell cancer of the urinary bladder: an alternative to classic prognostic indicators?. Urology. May 1999;53(5):1005-10. [Medline].
Shaw ME, Elder PA, Abbas A, Knowles MA. Partial allelotype of schistosomiasis-associated bladder cancer. Int J Cancer. Mar 1 1999;80(5):656-61. [Medline]. [Full Text].
Habuchi T, Takahashi R, Yamada H, Ogawa O, Kakehi Y, Ogura K, et al. Influence of cigarette smoking and schistosomiasis on p53 gene mutation in urothelial cancer. Cancer Res. Aug 15 1993;53(16):3795-9. [Medline]. [Full Text].
Ramchurren N, Cooper K, Summerhayes IC. Molecular events underlying schistosomiasis-related bladder cancer. Int J Cancer. Jul 28 1995;62(3):237-44. [Medline].
Warren W, Biggs PJ, el-Baz M, Ghoneim MA, Stratton MR, Venitt S. Mutations in the p53 gene in schistosomal bladder cancer: a study of 92 tumours from Egyptian patients and a comparison between mutational spectra from schistosomal and non-schistosomal urothelial tumours. Carcinogenesis. May 1995;16(5):1181-9. [Medline].
Abdulamir AS, Hafidh RR, Kadhim HS, Abubakar F. Tumor markers of bladder cancer: the schistosomal bladder tumors versus non-schistosomal bladder tumors. J Exp Clin Cancer Res. Feb 25 2009;28:27. [Medline]. [Full Text].
Przybojewska B, Jagiello A, Jalmuzna P. H-RAS, K-RAS, and N-RAS gene activation in human bladder cancers. Cancer Genet Cytogenet. Aug 2000;121(1):73-7. [Medline].
Rabbani F, Cordon-Cardo C. Mutation of cell cycle regulators and their impact on superficial bladder cancer. Urol Clin North Am. Feb 2000;27(1):83-102, ix. [Medline].
Guo CC, Gomez E, Tamboli P, Bondaruk JE, Kamat A, Bassett R, et al. Squamous cell carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical study of 16 cases. Hum Pathol. Oct 2009;40(10):1448-52. [Medline].
Badawi AF, Cooper DP, Mostafa MH, Aboul-Azm T, Barnard R, Margison GP, et al. O6-alkylguanine-DNA alkyltransferase activity in schistosomiasis-associated human bladder cancer. Eur J Cancer. 1994;30A(9):1314-9. [Medline].
Badawi AF, Mostafa MH, Aboul-Azm T, Haboubi NY, O'Connor PJ, Cooper DP. Promutagenic methylation damage in bladder DNA from patients with bladder cancer associated with schistosomiasis and from normal individuals. Carcinogenesis. May 1992;13(5):877-81. [Medline].
Fadl-Elmula I, Gorunova L, Lundgren R, Mandahl N, Forsby N, Mitelman F, et al. Chromosomal abnormalities in two bladder carcinomas with secondary squamous cell differentiation. Cancer Genet Cytogenet. Apr 15 1998;102(2):125-30. [Medline].
Lundgren R, Elfving P, Heim S, Kristoffersson U, Mandahl N, Mitelman F. A squamous cell bladder carcinoma with karyotypic abnormalities reminiscent of transitional cell carcinoma. J Urol. Aug 1989;142(2 Pt 1):374-6. [Medline].
Vanni R, Scarpa RM, Nieddu M, Usai E. Cytogenetic investigation on 30 bladder carcinomas. Cancer Genet Cytogenet. Jan 1988;30(1):35-42. [Medline].
Faysal MH. Squamous cell carcinoma of the bladder. J Urol. Nov 1981;126(5):598-9. [Medline].
Richie JP, Waisman J, Skinner DG, Dretler SP. Squamous carcinoma of the bladder: treatment by radical cystectomy. J Urol. Jun 1976;115(6):670-2. [Medline].
Winkler HZ, Nativ O, Hosaka Y, Farrow GM, Lieber MM. Nuclear deoxyribonucleic acid ploidy in squamous cell bladder cancer. J Urol. Feb 1989;141(2):297-302. [Medline].
Shaaban AA, Javadpour N, Tribukait B, Ghoneim MA. Prognostic significance of flow-DNA analysis and cell surface isoantigens in carcinoma of bilharzial bladder. Urology. Mar 1992;39(3):207-10. [Medline].
Print
